June 23, 2021 11:19 AM EDT

Hutchmed/AstraZeneca lung cancer drug gets OK in China; Enanta reports PhIb data for their oral hepatitis B program

Josh Sullivan

Max Gelman

Senior Editor

A collaboration to treat non-small cell lung cancer between AstraZeneca and Hutchmed has been granted approval by Chinese regulators, the company announced Tuesday.

The approval …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Hutchmed/AstraZeneca lung cancer drug gets OK in China; Enanta reports PhIb data for their oral hepatitis B program

Josh Sullivan

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Bristol Myers reveals more job cuts in New Jersey

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Hutchmed/As­traZeneca lung can­cer drug gets OK in Chi­na; Enan­ta re­ports PhIb da­ta for their oral he­pati­tis B pro­gram

Senior Editor

Sign up to read this article for free.

more like this

Hutchmed/AstraZeneca lung cancer drug gets OK in China; Enanta reports PhIb data for their oral hepatitis B program